4.6 Article

COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry

期刊

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
卷 36, 期 11, 页码 3033-3040

出版社

WILEY
DOI: 10.1111/jgh.15588

关键词

COVID-19; Crohn's disease; Latin America; Ulcerative colitis

资金

  1. Helmsley Charitable Trust [2003-04445]
  2. National Center for Advancing Translational Sciences [UL1TR002489]
  3. Pfizer
  4. Takeda
  5. Janssen
  6. AbbVie
  7. Lilly
  8. Genentech
  9. Boehringer Ingelheim
  10. Bristol Myers Squibb
  11. Arenapharm
  12. Celltrion
  13. [T32DK007634]
  14. [K23KD111995-01A1]

向作者/读者索取更多资源

In Latin America, IBD patients diagnosed with COVID-19 have similar outcomes to global data, with risk factors for severe COVID-19 being similar to previous reports.
Background and Aim One of the most impacted regions by the pandemic globally, Latin America is facing socioeconomic and health-care challenges that can potentially affect disease outcomes. Recent data suggest that inflammatory bowel disease (IBD) patients do not have an increased risk of the development of COVID-19 complications. However, the impact of COVID-19 on IBD patients living in least developed areas remains to be fully elucidated. This study aims to describe the outcomes of IBD patients diagnosed with COVID-19 in countries from Latin America based on data from the SECURE-IBD registry. Methods Patients from Latin America enrolled in the SECURE-IBD registry were included. Descriptive analyses were used to summarize clinical and sociodemographic characteristics. The studied outcomes were (i) a composite of need for intensive care unit admission, ventilator use, and/or death (primary outcome) and (ii) a composite of any hospitalization and/or death (secondary outcome). Multivariable regression was used to identify risk factors of severe COVID-19. Results During the study period, 230 cases (Crohn's disease: n = 115, ulcerative colitis: n = 114, IBD-unclassified [IBD-U]: n = 1) were reported to the SECURE-IBD database from 13 different countries. Primary outcome was observed in 17 (7.4%) patients, and the case fatality rate was 1.7%. In the adjusted multivariable model, the use of systemic corticosteroids (odds ratio [OR] 10.97; 95% confidence interval [CI]: 3.44-34.99) was significantly associated with the primary outcome. Older age (OR 1.03; 95% CI: 1.00-1.05), systemic corticosteroids (OR 9.33; 95% CI: 3.84-22.63), and the concomitant presence of one (OR 2.14; 95% CI: 0.89-5.15) or two (OR 10.67; 95% CI: 1.74-65.72) comorbidities were associated with the outcome of hospitalization or death. Conclusion Inflammatory bowel disease patients with COVID-19 in Latin America appear to have similar outcomes to the overall global data. Risk factors of severe COVID-19 are similar to prior reports.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据